Association of Duration of Sleep and Cardiovascular and Metabolic Comorbidities in Sleep Apnea Syndrome

Table 3

Association between reported sleep duration and cardiovascular and metabolic comorbidities in the models adjusting for other risk factors.

	Whole group		OSAS patients
Comorbidities and duration of sleep	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
HT
6 hours or less	1.0 (0.6–1.8)	0.6 (0.3–1.3)	1.3 (0.6–2.7)	0.7 (0.2–1.7)
8.5–10 hours	1.0 (0.4–2.2)	0.7 (0.3–1.8)	1.4 (0.5–4.4)	0.8 (0.2–2.7)
DM
6 hours or less	1.6 (0.7–3.5)	1.2 (0.5–3.0)	2.7 (0.8–8.5)	2.3 (0.7–7.8)
8.5–10 hours	1.7 (0.6–4.8)	1.2 (0.4–3.7)	3.7 (0.9–15.9)	2.3 (0.4–11.4)
CHD
6 hours or less	1.1 (0.5–2.9)	1.2 (0.4–3.8)	3.6 (1.1–11.3)	5.8 (1.0–32.6)
8.5–10 hours	0.4 (0.1–2.1)	0.3 (0.06–2.3)	NA	NA

Adjustments were made for OSAS, age, gender, and BMI in all models, and additionally for smoking status in HT and for smoking status and educational status in CHD.
For duration of sleep, 7-8 hours was considered as the reference category.
Significant findings are marked in bold type.
HT: hypertension, DM: diabetes mellitus, CHD: coronary heart disease, and OSAS: obstructive sleep apnea syndrome.